- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05654909
Prehospital Assessment Units - a Matched Cohort Study
This study aimed to evaluate the prehospital assessment unit (PAU) by admission within 48 hours, 7 days, respectively and on survival.
The PAU should increase focus on a patient-centered approach with the capability to make advanced assessments of patients to reduce unnecessary transportation. Further, this paramedic assessment program could positively impact the healthcare system by reducing admissions to emergency departments.
The PAU is operated by paramedics who have additional education, and they are capable of testing and monitoring certain conditions at the scene - in the home of the patients. The paramedics decide if the patient requires admission to the hospital or if the patient could stay at home. They are consulting physicians on call by phone.
This retrospective cohort study included data from patients assessed by the PAU between November 1st 2021, and October 1st 2022.
Non-PAU patients were selected from the 1-1-2 calls (the European version of 9-1-1) EMS and were collected based on the same criteria as the patients assessed by the PAU. The control ratio was 1:10 for cases to increase power. The non-PAU patients were matched on sex and age (within 5-year ranges). Matching was performed using incidence density sampling, where controls were selected for each case on the week of 1-1-2 call.
Study Overview
Status
Intervention / Treatment
Detailed Description
The demand for healthcare is increasing, stressing the need for adaptive Emergency Medical Services (EMS). This development was also illustrated in a Danish cohort study from 2017. The authors reported an increase in the annual number of patients assessed by EMS by 67% between 2007 and 2014.Thus, the traditional role of paramedics is changing to establish a bridge between the community and the hospital by offering primary care services. Paramedic assessment units (PAU) were implemented in Region Zealand, Denmark in 2021 to accommodate the increased demand. The PAU should increase focus on a patient-centered approach with the capability to make advanced assessments of patients to reduce unnecessary transportation. Further, this paramedic assessment program could positively impact the healthcare system by reducing admissions to emergency departments.
While this approach is new in Denmark, variations of the approach have been implemented internationally for more than two decades.The PAU can be compared with the community paramedic units. Different community paramedic programs have arisen to address the regional requirements; different regional and national operation environments explain this regarding the population density and level of healthcare service. No exact definition is present, but these assessment programs generally focus on frail elderly and other high-needs patients.
The PAU is operated by paramedics who have additional education, and they do have point-of-care test facilities (POCT). The paramedics can monitor saturation, blood pressure and electrocardiogram, all of which are standard equipment of ambulances in Region Zealand. Further, the paramedic can measure C-reactive protein, analyse urine test strips (pH, glucose, acetoacetate, leucocytes, nitrite, protein and erythrocytes), blood glucose and analyse blood gas (pH, pO2, pCO2, lactate, sodium, potassium, calcium and creatinine).
The patients assessed by the PAU had four possible destinations: admittance to the E-Hospital, a unique regional arrangement in which the patient stays at home but is under virtual surveillance by physicians and nurses. Alternatively, the patient was admitted to the E-hospital at local acute community-based facilities. Third, the patient was admitted to the emergency department at the hospital and finally, the PAU examined the patient at home without further follow-up. The decision was made between the physicians at the E-Hospital and the paramedic on the scene.
While the evidence supporting PAU is promising, convincing data from well-designed studies focusing on the impact of PAU on health outcomes and patient safety are still being determined.
This retrospective cohort study was conducted to compare individuals treated by PAU with a control group of matched individuals not treated by PAU. Thus, the primary objective of this study was:
- To identify patients among cases who were admitted to the emergency department within 48 hours and 7 days after consultation with the PAU, respectively.
- Secondary, to identify patients admitted to the emergency department within 6 hours from the initial call to the medical emergency number.
- Finally, to identify 30-day survival.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Næstved, Denmark
- Prehospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- expectations of undergoing an uncomplicated illness progression
- green or yellow level of triage based on the ABCDE approach (red, orange, yellow, green, blue levels of triage.
Exclusion Criteria:
- gynaecological disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
PAU group
The PAU group were patients calling 1-1-2 assigned for the prehospital assessment unit,
|
The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand.
Further details are mentioned in the description.
|
|
non PAU group
The non PAU group were selected from the 1-1-2 calls (the European version of 9-1-1) EMS and were collected based on the same criteria as the patients assessed by the PAU.
The control ratio was 1:10 for cases to increase power.
Controls were matched on sex and age (within 5-year ranges).
Matching was performed using incidence density sampling, where controls were selected for each case on the week of 1-1-2 call.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Admission within 48 hours
Time Frame: 48 hours
|
Dichotomous variable of admission within two days after intial call
|
48 hours
|
|
Admission within 7 days
Time Frame: 7 dats
|
Dichotomous variable of admission within seven days after intial call
|
7 dats
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Admission within 6 hours
Time Frame: 6 hours
|
Dichotomous variable of admission within 6 hours from intial call
|
6 hours
|
|
30-day survival
Time Frame: 30-day
|
30-day survival from initial call
|
30-day
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Andersen MS, Johnsen SP, Sorensen JN, Jepsen SB, Hansen JB, Christensen EF. Implementing a nationwide criteria-based emergency medical dispatch system: a register-based follow-up study. Scand J Trauma Resusc Emerg Med. 2013 Jul 9;21:53. doi: 10.1186/1757-7241-21-53.
- Christensen EF, Bendtsen MD, Larsen TM, Jensen FB, Lindskou TA, Holdgaard HO, Hansen PA, Johnsen SP, Christiansen CF. Trends in diagnostic patterns and mortality in emergency ambulance service patients in 2007-2014: a population-based cohort study from the North Denmark Region. BMJ Open. 2017 Aug 21;7(8):e014508. doi: 10.1136/bmjopen-2016-014508.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHV_2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
EyeGene Inc.BMI KoreaRecruitingMeningococcal InfectionsSouth Korea
-
University Hospital, Strasbourg, FranceRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting
-
Arba Minch UniversityActive, not recruiting
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruiting
-
Han TongyanCompletedLower Respiratory Tract Infections | RSV InfectionsChina
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdRecruitingRespiratory Syncytial Virus InfectionsChina
-
GlaxoSmithKlineRecruiting
-
ShionogiRecruitingRespiratory Syncytial Virus InfectionsUnited States, Bulgaria, South Africa, Poland, Japan
-
Kevin WinthropAN2 Therapeutics, IncRecruitingMycobacterium Abscessus InfectionUnited States
Clinical Trials on Prehospital assessment unit
-
Azienda Usl di BolognaCompletedTrauma Abdomen | Liver Injury | Trauma SplenicItaly
-
Future University in EgyptRecruiting
-
Medical University of ViennaCompleted
-
Medical University of ViennaActive, not recruitingEchocardiography | Acute DyspneaAustria
-
Hôpital le VinatierCompleted
-
University Hospital, Basel, Switzerlandpropatient ForschungsstiftungRecruiting
-
Helsinki University Central HospitalCompleted
-
Peking University People's HospitalBeijing Emergency Medical Center; Beijing Red Cross Emergency CenterCompletedEmergencies [Disease/Finding]China
-
Centre Hospitalier Intercommunal de Toulon La Seyne...Completed
-
Siriraj HospitalRecruitingOut-of-hospital Cardiac Arrest (OHCA)Thailand